Ordinary Shares International Reporting
Verified Company Profile 1/06/2017
Contact Info
  • 700 Collip Circle,
  • Suite 114
  • London, ONT N6G 4X8
  • Canada

Business Description

Financial Reporting/Disclosure
Reporting Status International Reporting: TSX Venture Exchange
Audited Financials Audited
Latest Report Oct 31, 2016 Annual Report
CIK 0001491434
Fiscal Year End 10/31
OTC Marketplace OTCQB
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: Canada
Year of Inc. 1998
Employees 10 a/o Dec 31, 2016
Company Officers/Contacts
Philip M. Toleikis CEO
Scott Langille CFO
Company Directors
Frank Alfred Holler Chairman
Jeffrey Bacha
James Parsons
Philip M. Toleikis
Bruce Allen Weber
Service Providers
Accounting/Auditing Firm
Davidson & Company LLP
609 Granville St
Suite 1200
Vancouver, BC, V7Y 1G6
Securities Counsel
McMillan LLP OTCQX Sponsor
Royal Centre, 1500-1055 W Georgia
Vancouver, BC, V6E 4N7
Investor Relations Firm
Ray Matthew & Associates
128 West Cordova Street
Suite 601
Vancouver, BC, V6B 0E8
Company History
  • Formerly=Pheromone Sciences Corp. until 3-07
SEOVF Security Details
Share Structure
Market Value1 $30,928,533 a/o Mar 27, 2017
Authorized Shares Unlimited a/o Oct 31, 2016
Outstanding Shares 156,679,498 a/o Oct 31, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float 155,558,748 a/o Oct 31, 2016
Par Value No Par Value
Transfer Agent(s)
CST Trust Company
Shareholders of Record 99 a/o Oct 31, 2016
Non US Stock Exchange Listing
SVA - TSX Venture Exchange - Qualified
Short Selling Data
Short Interest 0 (-100%)
Aug 15, 2016
Significant Failures to Deliver No

1Market Value calculated only for respective security